ReviewExperimental hematology2017
Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies.
Review in Experimental hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Pooled it
- Pooled it
- Meta-analysis of the association between dietary inflammatory index (DII) and upper aerodigestive tract cancer risk.Medicine · 2020Pooled it
- Trial
- PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-NeupogenBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019Trial
- Colitis-Associated Colorectal Cancer-STAT3 Inhibition as a Preventive Strategy.International journal of molecular sciences · 2026Article
- Safety assessment of Neulasta® (pegfilgrastim) in patients with solid tumors: a real-world adverse event analysis from the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The role of neutrophils in the pathogenesis of abdominal aortic aneurysms.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Neutrophil CD14 is a driver and a therapeutic target for deep vein thrombosis.Blood advances · 2026Article
- Indirubin and Retinoic Acid Show Binding Affinity to Monocyte Biomarker CSF3R in Parkinson's Disease.Journal of clinical laboratory analysis · 2026Article
- Aging changes the mechanism that underlies JAK2 modulation of neutrophil function.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- The Role of Granulocyte Colony-Stimulating Factor in Endometrial Preparation for Embryo Implantation in In Vitro Fertilization.Life (Basel, Switzerland) · 2026Review
- Tuning of G-CSFR signaling by de novo-designed agonists.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Article
- Changes in gut microbiota predict neutropenia after induction treatment in childhood acute lymphoblastic leukemia.Blood advances · 2025Article
- Early Neutrophil Activation in Psoriatic Skin at Relapse Following Dead Sea Climatotherapy.Experimental dermatology · 2025Article
- Distribution and clinicopathological characteristics of G-CSF expression in tumor cells and stromal cells in upper tract urothelial carcinoma.Journal of cancer research and clinical oncology · 2024Article
- Genomic Insights into Host Susceptibility to Periprosthetic Joint Infections: A Comprehensive Literature Review.Microorganisms · 2024Review
- A strategy to design protein-based antagonists against type I cytokine receptors.PLoS biology · 2024Article
- Upregulation of MMPs in placentas of patients with gestational diabetes mellitus: Involvement of the PI3K/Akt pathway.Heliyon · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Granulocyte colony-stimulating factor is a hematopoietic cytokine that stimulates neutrophil production and hematopoietic stem cell mobilization by initiating the dimerization of homodimeric granulocyte colony-stimulating factor receptor. Different mutations of CSF3R have been linked to a unique spectrum of myeloid disorders and related malignancies. Myeloid disorders caused by the CSF3R mutations include severe congenital neutropenia, chronic neutrophilic leukemia, and atypical chronic myeloid leukemia. In this review, we provide an analysis of granulocyte colony-stimulating factor receptor, various mutations, and their roles in the severe congenital neutropenia, chronic neutrophilic leukemia, and malignant transformation, as well as the clinical implications and some perspective on approaches that could expand our knowledge with respect to the normal signaling mechanisms and those associated with mutations in the receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.